The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.

Aura Biosciences, a US-based cancer therapy developer backed by pharmaceutical firms Lundbeck and Chiesi Group and scientific measurement system provider Li-Cor Biosciences, has filed for an initial public offering.

The IPO has a $100m placeholder figure and is set to take place on the Nasdaq Global Market. Cowen, SVB Leerink and Evercore are serving as joint underwriters for the offering and are being joined by lead manager BTIG.

Founded in 2009, Aura has a pipeline of ocular and urologic…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn